Skip to main content

4 Result(s)

within Shingo Matsushima Remove this filter

and

  1. Article

    Open Access

    Application of the CDK9 inhibitor FIT-039 for the treatment of KSHV-associated malignancy

    Chronic infection with Kaposi’s sarcoma-associated herpes virus (KSHV) in B lymphocytes causes primary effusion lymphoma (PEL), the most aggressive form of KSHV-related cancer, which is resistant to convention...

    Tetsunori Sakamoto, Masahiko Ajiro, Akira Watanabe, Shingo Matsushima… in BMC Cancer (2023)

    Download PDF (4579 KB) View Article

  2. Article

    Open Access

    Author Correction: Therapeutic manipulation of IKBKAP mis-splicing with a small molecule to cure familial dysautonomia

    Masahiko Ajiro, Tomonari Awaya, Young ** Kim, Kei Iida… in Nature Communications (2021)

    Download PDF (406 KB) View Article

  3. Article

    Open Access

    Therapeutic manipulation of IKBKAP mis-splicing with a small molecule to cure familial dysautonomia

    Approximately half of genetic disease-associated mutations cause aberrant splicing. However, a widely applicable therapeutic strategy to splicing diseases is yet to be developed. Here, we analyze the mechanism...

    Masahiko Ajiro, Tomonari Awaya, Young ** Kim, Kei Iida… in Nature Communications (2021)

    Download PDF (2322 KB) View Article

  4. No Access

    Article

    Conversion of 4-aminobutyraldehyde to γ-aminobutyric acid in striatum treated with semicarbazide and kainic acid

    4-Aminobutyraldehyde (ABAL) has been shown to cross the blood-brain barrier and to be converted rapidly to γ-aminobutyric acid (GABA) in various regions of the brain. In this paper, the formation of GABA from ...

    Shingo Matsushima, Seiji Hori, Makoto Matsuda in Neurochemical Research (1986)